Maintenance Regimens Expand in HER2-Positive Metastatic Breast Cancer

(MedPage Today) -- At the American Society of Clinical Oncology (ASCO) meeting, updated HER2CLIMB-05 findings on the addition of tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) added to...